Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital lifts Vistry price target after results

(Sharecast News) - RBC Capital Markets lifted its price target on Vistry on Thursday after the housebuilder's half-year results a day earlier, to reflect progress made. The bank kept its rating at 'underperform' but upped the price target to 500p from 475p.

"What a difference almost a year makes - following a very challenging eleven months Vistry is back to its usual self of seeing its glass significantly more than half full," RBC said.

"Riding on the back of a fully UK Government backed social and affordable housing sector Vistry is looking to grow profits for shareholders.

"The scene is set and the lighting on set is flattering, but the actors still need to play their part for the show to be a success. Interestingly, despite the upbeat tone guidance was unchanged, suggesting Vistry is not fully out of the woods just yet."

RBC said it was not ready to change its rating yet, however.

"Vistry is turning its fortunes around, but as they say, 'talk is cheap, but money buys houses'; we are not ready to change our rating yet, but our PT moves to 500p reflect the progress made."

At 1050 BST, the shares were up 2.3% at 582.20p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.